Bristol Myers: positive data in pulmonary fibrosis

(CercleFinance.com) - Bristol Myers Squibb's Investigational LPA1 Antagonist Reduces Rate of Lung Function Decline in Progressive Pulmonary Fibrosis Cohort of Phase 2 Study.


The study showed that twice-daily administration of 60 mg of BMS-986278 over 26 weeks reduced the rate of decline in percent predicted forced vital capacity (ppFVC) by 69% compared to placebo (overall, 38% of patients in the study received background antifibrotic therapy).

These data will be presented during the Abstracts Leading to Evolution in Respiratory Medicine Trials (ALERT) session 1 at the European Respiratory Society (ERS) 2023 International Congress held September 9-13 in Milan, Italy.

“The Phase 2 progressive pulmonary fibrosis results, which demonstrate consistent efficacy with or without background antifibrotic therapy and a favorable tolerability profile, reinforce the potential of BMS-986278 and highlight advancements in the space as we race to find a potential new standard of care.” said Professor Tamera J. Corte, clinical trial investigator and Consultant Respiratory Physician and Director of Interstitial Lung Disease, Department of Respiratory Medicine, Royal Prince Alfred Hospital.

Copyright (c) 2023 CercleFinance.com. All rights reserved.